IMCORE

Genentech, Inc.

Application Filed: 2016-11-22
Trademark Application Details
Trademark Logo IMCORE

Mark For: IMCORE® trademark registration is intended to cover the categories of research and development of advanced learning technologies and teaching methods to identify approaches to extend the benefit of cancer immunotherapy to patients and collaborate to identify new treatment approaches, to rapidly initiate clinical trials and to aggregate and share data to accelerate progress in the field of cancer immunotherapy. [all]

Status

2020-01-11 UTC
LIVE APPLICATION Published for Opposition
A pending trademark application has been examined by the Office and has been published in a way that provides an opportunity for the public to oppose its registration.


Research OneLook Acronym Finder
Serial Number87245470
Registration Number6731937
Mark Literal ElementsIMCORE
Mark Drawing Type4 - STANDARD CHARACTER MARK
Mark TypeSERVICE MARK
RegisterPRINCIPAL
Current LocationINTENT TO USE SECTION 2019-10-15
Basis1(b)
Class StatusACTIVE
Primary US Classes
  • 100: Miscellaneous
  • 101: Advertising and Business
Primary International Class
  • 042 - Primary Class
  • (Computer, scientific & legal) Scientific and technological services and research and design relating thereto: industrial analysis and research services; design and development of computer hardware and software; legal services.
Filed UseNo
Current UseNo
Intent To UseYes
Filed ITUYes
44D FiledNo
44E CurrentNo
66A CurrentNo
Current BasisNo
No BasisNo
Law Office AssignedL90
Employee NameLIU, PHILIP HUAI-EN

Timeline

2016-11-22Application Filed
2019-01-07Location: TMEG LAW OFFICE 109 - EXAMINING ATTORNEY ASSIGNED
2019-01-07Status: Live/Pending
2019-01-07Transaction Date
2019-08-20Published
2019-08-20Published for Opposition
2019-10-15Location: INTENT TO USE SECTION
2019-10-15Status: Notice of Allowance (NOA) sent (issued) to the applicant. Applicant must file a Statement of Use or Extension Request within six
2022-05-24Trademark Registered

Trademark Parties (Applicants & Owners)

Party: GENENTECH, INC.
Address1 DNA WAY SOUTH SAN FRANCISCO, CALIFORNIA UNITED STATES 940804990
Legal Entity TypeCorporation
Legal Entity StateDELAWARE

Attorney of Record

GENENTECH, INC.
1 DNA WAY
SOUTH SAN FRANCISCO, CA 94080-4990


Good, Services, and Codes


IC 042. US 100 101. G & S: Research and development of advanced learning technologies and teaching methods to identify approaches to extend the benefit of cancer immunotherapy to patients and collaborate to identify new treatment approaches, to rapidly initiate clinical trials and to aggregate and share data to accelerate progress in the field of cancer immunotherapy

International Codes:42
U.S. Codes:100,101
Type CodeType
GS0421Research and development of advanced learning technologies and teaching methods to identify approaches to extend the benefit of cancer immunotherapy to patients and collaborate to identify new treatment approaches, to rapidly initiate clinical trials and to aggregate and share data to accelerate progress in the field of cancer immunotherapy
GS0421Research and development of advanced learning technologies and teaching methods to identify approaches to extend the benefit of cancer immunotherapy to patients and collaborate to identify new treatment approaches, to rapidly initiate clinical trials and to aggregate and share data to accelerate progress in the field of cancer immunotherapy

Trademark Filing History

DescriptionDateProceeding Number
NOA E-MAILED - SOU REQUIRED FROM APPLICANT2019-10-15
PUBLISHED FOR OPPOSITION2019-08-20
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED2019-08-20
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED2019-07-31
APPROVED FOR PUB - PRINCIPAL REGISTER2019-07-15
TEAS/EMAIL CORRESPONDENCE ENTERED2019-07-1266121
CORRESPONDENCE RECEIVED IN LAW OFFICE2019-07-1266121
TEAS/EMAIL CORRESPONDENCE ENTERED2019-07-0388889
TEAS RESPONSE TO OFFICE ACTION RECEIVED2019-07-03
CORRESPONDENCE RECEIVED IN LAW OFFICE2019-07-0388889
NOTIFICATION OF NON-FINAL ACTION E-MAILED2019-01-076325
NON-FINAL ACTION WRITTEN2019-01-0792994
NON-FINAL ACTION E-MAILED2019-01-076325
LIE CHECKED SUSP - TO ATTY FOR ACTION2018-12-1466121
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED2018-05-0966121
ASSIGNED TO LIE2018-05-0966121
SUSPENSION LETTER WRITTEN2017-10-2592994
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED2017-10-256332
LETTER OF SUSPENSION E-MAILED2017-10-256332
TEAS/EMAIL CORRESPONDENCE ENTERED2017-10-2188889
TEAS RESPONSE TO OFFICE ACTION RECEIVED2017-10-20
CORRESPONDENCE RECEIVED IN LAW OFFICE2017-10-2088889
NOTIFICATION OF NON-FINAL ACTION E-MAILED2017-04-216325
NON-FINAL ACTION WRITTEN2017-04-2192994
NON-FINAL ACTION E-MAILED2017-04-216325
LETTER OF PROTEST ACCEPTED2017-04-18
NOTIFICATION OF NON-FINAL ACTION E-MAILED2017-01-056325
NON-FINAL ACTION WRITTEN2017-01-0592994
NON-FINAL ACTION E-MAILED2017-01-056325
ASSIGNED TO EXAMINER2016-12-2892994
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM2016-11-30
NEW APPLICATION ENTERED IN TRAM2016-11-25

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.

© 2024 USPTO.report | Privacy Policy | Resources | RSS Feed of Trademarks | Trademark Filings Twitter Feed